Purchase by Sanjay Shukla of 15000 shares of ATyr Pharma

About 67% of ATyr Pharma's investor base is looking to short. The analysis of current outlook of investing in ATyr Pharma suggests that many traders are alarmed regarding ATyr Pharma's prospects. The current market sentiment, together with ATyr Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use ATyr Pharma stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Atyr Pharma Inc director. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
ATyr insider trading alert for perchase of common stock by Sanjay Shukla, President and CEO, on 1st of August 2023. This event was filed by Atyr Pharma Inc with SEC on 2023-08-01. Statement of changes in beneficial ownership - SEC Form 4

ATyr Pharma Fundamental Analysis

We analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

ATyr Pharma is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

ATyr Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ATyr Pharma stock to make a market-neutral strategy. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics with similar companies.

Peers

ATyr Pharma Related Equities

XFORX4 Pharmaceuticals   11.43   
0%
100.0%
TERNTerns Pharmaceuticals   7.82   
0%
68.0%
HOOKHookipa Pharma   6.90   
0%
60.0%
MREOMereo BioPharma   4.71   
0%
41.0%
ABOSAcumen Pharmaceuticals   2.73   
0%
23.0%
INZYInozyme Pharma   2.64   
0%
23.0%
PDSBPDS Biotechnology   1.90   
0%
16.0%
DAWNDay One   1.33   
0%
11.0%
AMLXAmylyx Pharmaceuticals   0.00   
0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in ATyr Stock

If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Transaction History
View history of all your transactions and understand their impact on performance